Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $117.82

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $117.8182.

Several equities research analysts have recently issued reports on the stock. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush upped their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th.

Dianthus Therapeutics Trading Up 0.6%

NASDAQ:DNTH opened at $104.49 on Friday. The stock has a 50-day moving average price of $91.14 and a 200 day moving average price of $76.70. The stock has a market capitalization of $5.71 billion, a P/E ratio of -25.30 and a beta of 1.20. Dianthus Therapeutics has a 12-month low of $18.08 and a 12-month high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, research analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 87,779 shares of company stock valued at $7,985,235 in the last 90 days. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after acquiring an additional 139 shares during the last quarter. First Horizon Corp bought a new position in shares of Dianthus Therapeutics during the 1st quarter valued at approximately $32,000. Virtus Investment Advisers LLC grew its holdings in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.